Greenwich LifeSciences, Inc.
GP2, an immunotherapy to prevent breast cancer recurrence
Follows are private to you and power your alerts
Updated · greenwichlifesciences.com
- Sector
- Biotech
- Headquarters
- STAFFORD, TX
- Latest Form D
- $2.5M, Jun 2024
- Total capital
- $2.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $2.5M
- 1 Form D · last Jun 2024
- 28 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 7 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$2.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- David McWilliamsDirectorNamed in SEC Form D filings
- Eric RotheDirectorNamed in SEC Form D filings
- F. Joseph DaughertyExecutive Officer, DirectorNamed in SEC Form D filings
- Kenneth HallockDirectorNamed in SEC Form D filings
- Snehal PatelExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 7- PendingMethods For Reversing A Suppressed Immune State To Increase Survival In A SubjectUSPTOApplication 18839849
- PendingMethods For Assessing An Immune Response And Predicting Cancer Recurrence And Assessment Of Current And Prior Cancer StatusUSPTOApplication 18709972
- PendingMethods For Reversing A Suppressed Immune State To Increase Survival In A SubjectUSPTOApplication PCTUS2023014811
Show all 7 patent records
- Methods For Reversing A Suppressed Immune State To Increase Survival In A SubjectJul 24, 2025 · Application 18839849Pending
- Methods For Assessing An Immune Response And Predicting Cancer Recurrence And Assessment Of Current And Prior Cancer StatusJan 9, 2025 · Application 18709972Pending
- Methods For Reversing A Suppressed Immune State To Increase Survival In A SubjectApplication PCTUS2023014811Pending
- Methods For Assessing An Immune Response And Predicting Cancer Recurrence And Assessment Of Current And Prior Cancer StatusApplication PCTUS2022050474Pending
- Methods For Assessing Baseline Immune Response And Predicting Cancer Recurrence And Assessment Of Prior Cancer Status, Methods For Administering GP2 To Reverse Reduced Immune State, Reduce Recurrence Rate, And Increase Disease Free Survival, Methods For Use Of Injection Site Reactions (isr) As A Proxy For Delayed Type Hypersensitivity Test, And Methods For Administering GP2 Boosters And Measuring Immune Response And Reduce Recurrence Rate And Increase Disease Free SurvivalApplication 63329409Pending
- Methods For Assessing Baseline Immune Response And Predicting Cancer Recurrence And Assessment Of Prior Cancer Status, Methods For Administering GP2 To Reverse Reduced Immune State, Reduce Recurrence Rate, And Increase Disease Free Survival, And Methods For Use Of Injection Site Reactions (isr) As A Proxy For Delayed Type Hypersensitivity TestApplication 63317601Pending
- Methods For Assessing Baseline Immune Response And Predicting Cancer Recurrence And Assessment Of Prior Cancer StatusApplication 63280958Pending
Related companies, and why
- Cantai Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- GeorgiamuneSimilar federal contract value in Biotech · null in contracts
- Rinascera Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cellective BioTherapy, Inc.Similar federal contract value in Biotech · null in contracts
- Elion, Inc.Similar federal contract value in Biotech · null in contracts
- Firefly BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .